ESTRO Annual Report 2018

ECCO2018: European Cancer Congress - From science to real-life oncology 7-9 September 2018 | Vienna, Austria

Over 350 experts and leaders from across the cancer care stakeholder communities met at the ECCO 2018 European Cancer Summit during the Austrian EU Presidency in Vienna on 7-9 September. They decided on how Europe can improve the ways by which quality of cancer care is measured, integration of cancer care is made reality, and how financial discrimination experienced by survivors of cancer can be alleviated.

The three high-level, time-based goals, passed as resolutions by the Summit were:

1. By 2023, an agreed set of core standards and evidence-based indicators (based on processes and patient outcomes) to measure the quality of all cancer services in European countries should be in place. 2. By 2025, all national cancer plans in Europe should contain ambitious and measurable goals and actions to improve the integration of primary care professionals and informal carers within the multidisciplinary care given to patients. 3. By 2025, in respect to accessing financial services*, the right of cancer survivors not to declare their cancer ten years after the end of the active treatment**, and five years if they had cancer under the age of 18, should be codified across European countries. A set of defined actions will transpose the resolutions into practice. The complete list of resolutions and supporting actions are available at www.eccosummit.eu/Resolutions

Perspectives of Advanced Radiotherapy in Middle Income Countries 26-28 September 2018 | Tehran, Iran

The advent of multileaf collimators in 90s and the ever increasing access to fast computers laid the foundation for a radical change in the practice of radiation therapy. Advanced technology emerged together with numerous conceptual and technical ramifications in treatment calculation and delivery. Merged with imaging, advanced radiotherapy in developed countries has become much resource- intensive, team-based and complex; nevertheless, it is now the new norm. Modern treatment technology is inevitably – though not comprehensively– finding its way to the clinics of many developing countries, where the industrial work culture and technical network has not yet flourished as much. In developing countries, especially where private practice is allowed, there is a vibe towards purchasing fancier technologies to get a lead against other radiotherapy centres and potentially attract more patients as a result of selling the prestige of the new technology. The conference was programmed by ISCO, in scientific collaboration with ESTRO and benefitted from a world-class faculty in the field of radiation oncology.

41

Science Dissemination